

non-radiolabelled olaparib capsules to six patients. The primary aim was to investigate the metabolism, excretion and pharmacokinetics (PK) of olaparib in patients with advanced solid tumours.

Results: Six female patients (aged 34–72 years) were included. Data from one patient were excluded for PK analysis as she had received only half the total dose of olaparib with the planned dose of radioactivity (120 µCi). Absorption of olaparib was rapid, with maximum plasma concentrations (geometric mean 3556 ng/mL) observed at 1.5–2 hours (h) post dose. Following this, plasma concentrations declined polyphasically, and were below the limit of quantification by 16 to 24 h post dose. The geometric mean AUC was 19856 ng.h/mL, oral clearance was 4 to 14 L/h, apparent volume of distribution was 20 to 50 L, and the terminal half-life was between 2.4 and 4.7 h. Total plasma radioactivity concentrations were mostly higher than those of the parent compound, and these values declined in parallel. In addition, the mean ratio of the concentration of radioactivity in blood to plasma was 0.8, suggesting some association of olaparib-related material with cellular components of the blood. Mean total recovery (over 144 or 168 h) of the radioactive dose from all patients was 86%; 44% in the urine (15% as the parent compound) and 42% in the faeces. In most patients, the majority of the excreted radioactivity was recovered within 72 h of dosing.

Conclusions: After a single dose of olaparib 100 mg (50 mg contained [¹⁴C]), absorption was rapid and elimination occurred relatively quickly, mainly via the urine and faeces. Furthermore, these data indicate the presence of circulating metabolites and suggest association of olaparib and/or metabolites with the cellular components of blood.

406 POSTER Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease

D.C. Smith¹, A. Spira², J. De Grève³, L. Hart⁴, S. Holbrechts⁵, C.C. Lin⁶, M. Hussain¹, S. Herrick⁷, K. Houggy⁷, N. Vogelzang⁸. ¹University of Michigan, Department of Medicine, Ann Arbor, USA; ²Fairfax Northern Virginia Hematology-Oncology PC, NA, Fairfax, USA; ³Universitair Ziekenhuis Brussel, Department of Medical Oncology, Brussels, Belgium; ⁴Florida Cancer Specialists, NA, Fort Myers, USA; ⁵Center Hospitalier Universitaire Ambroise Paré, NA, Henegouwen, Belgium; ⁶National Taiwan University Hospital, Department of Oncology, Taipei, Taiwan; ⁷Exelixis Inc, NA, South San Francisco, USA; ⁸Comprehensive Cancer Centers of Nevada, NA, Las Vegas, USA

Background: XL184 is an oral potent inhibitor of MET, VEGFR2 and RET. Activation of the MET pathway promotes tumor growth, invasion, and metastasis. Overexpression of MET and/or its ligand HGF have been shown to correlate with prostate cancer metastasis to lymph nodes and bones, and disease recurrence. In addition, androgen ablation has been shown to upregulate MET signaling in preclinical studies. Targeting the MET pathway with XL184 may therefore be a promising treatment strategy. Preliminary data from the open label Lead-in Stage of a Phase 2 randomized discontinuation trial are presented showing the effects of XL184 in pts with CRPC.

Methods: Eligible pts have CRPC with measurable disease and have progressed on up to 1 prior non-hormonal systemic treatment after antiandrogen withdrawal. XL184 is administered open label at 100 mg free base equivalent (125 mg XL184-malate-salt) qd for 12 weeks (wks) (Lead-in Stage). Tumor response is assessed radiologically every 6 wks. Pts with partial or complete response (PR or CR) at wk 12 continue to receive XL184; pts with progressive disease (PD) discontinue XL184. Pts with SD at wk 12 are randomized 1:1 to receive XL184 or placebo. Cross-over from placebo to XL184 is allowed upon PD. Primary endpoints are objective response rate at wk 12 and progression free survival in the Randomized Stage. PSA levels will be correlated with clinical outcomes.

Results: A total of 16 pts have been enrolled with a median age of 69 years. The median number of prior non-hormonal systemic treatments was 1, with 7 pts receiving docetaxel. Of 9 pts who were evaluable (minimum 12 wks follow up) to date, 1 pt achieved a PR and 5 pts achieved SD for an overall disease control rate of 67% at wk 12. Two pts achieved a near complete resolution of tracer uptake on bone scan with one pt previously treated with docetaxel who attained a 41% reduction in measurable disease and a reduction of PSA > 50% at wk 12. Most frequently observed adverse events regardless of causality with CTCAE Grade ≥3 in the Lead-in Stage were fatigue and asthenia (each n=2).

Conclusions: Preliminary results suggest that XL184 is active in CRPC pts who failed prior treatment. XL184 was generally well tolerated. Updated efficacy and safety results will be presented.

407 POSTER Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease

I. Vergote¹, A. Sella², C. Bedell³, L. Ramondetta⁴, G.I. Shapiro⁵, K. Balic⁶, E. Prokopczuk⁶, L. Sauer⁶, L. Tseng⁶, R. Berger⁷. ¹University Hospital Leuven, Gynecological Oncology, Leuven, Belgium; ²Assaf Harofeh Medical Centre, Department of Oncology, Zerifin, Israel; ³Mary Crowley Medical Research Center, Dallas, USA; ⁴MD Anderson Cancer Center, Gynecologic Oncology, Houston, USA; ⁵Dana Farber Cancer Institute, Department of Medical Oncology, Boston, USA; ⁶Exelixis Inc., South San Francisco, USA; ⁷Chaim Sheba Medical Center, Institute of Oncology&Radiotherapy, Tel Hashomer, Israel

Background: XL184 is an oral, potent inhibitor of MET, VEGFR2 and RET. MET overexpression has been observed in advanced ovarian cancer (OC). Anti-VEGF pathway agents have shown clinical benefit in pts with OC. Co-targeting of the MET and VEGF signaling pathways using XL184 may therefore be a promising treatment strategy. Preliminary data from the open label Lead-in Stage of a Phase 2 randomized discontinuation trial are presented showing the effects of XL184 in pts with OC.

Methods: Eligible pts have advanced epithelial OC, primary peritoneal, or fallopian tube cancer with measurable disease. Up to 3 prior regimens are allowed for platinum-resistant (disease recurrence within 6 months after last platinum based chemotherapy [PBC]) and refractory pts, and up to 4 for platinum-sensitive (disease recurrence >6 months after last PBC) pts. XL184 is administered open label at 100 mg free base equivalent (125 mg XL184-malate-salt) qd for 12 weeks (wks) (Lead-in Stage). Tumor response is assessed radiologically every 6 wks. Pts with partial or complete response (PR or CR) at week (wk) 12 continue to receive XL184; pts with progressive disease (PD) discontinue XL184. Pts with stable disease (SD) at wk 12 are randomized 1:1 to receive XL184 or placebo (P). Cross-over from P to XL184 is allowed upon PD. Primary endpoints are objective response rate at wk 12 and progression free survival in the Randomized Stage. CA125 levels will be correlated with clinical outcomes.

Results: A total of 21 pts have been enrolled to date with a median age of 60 years. The median number of prior systemic treatments was 2. Of the 7 pts who were evaluable (minimum 12 wk follow up) to date, 3 pts achieved an unconfirmed PR and 4 pts achieved SD. One pt with platinum-sensitive serous adenocarcinoma (SAC) achieved a 34% tumor reduction at wk 12. One pt with platinum-resistant SAC experienced a CA125 response per GCIG criteria and a 24% tumor decrease at wk 12. A second pt with platinum-resistant SAC achieved re-stabilization of PD after cross-over from P to XL184. Most frequently observed adverse events regardless of causality with CTCAE Grade ≥3 in the Lead-in Stage include rash, palmar-plantar erythrodysesthesia syndrome, pruritus, pulmonary embolism, staphylococcal infection (each n=1).

Conclusions: Preliminary results suggest that XL184 is active in pts with advanced OC who failed prior treatment. XL184 was generally well tolerated. Updated efficacy and safety results will be presented.

408 POSTER Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)

E. Van Cutsem¹, W.C. Su², J. Davis³, N. Haas⁴, T.A. Samuel⁵, C.J. Tsao⁶, T.S. Yang⁷, H. Brandy⁸, G. Mann⁸, A. Cohn⁹. ¹University Hospitals Leuven, Department of Digestive Oncology, Leuven, Belgium; ²National Chen Kung University Hospital, Department of Internal Medicine, Tainan, Taiwan; ³Kansas City Cancer Center, Lee's Summit, USA; ⁴University of Pennsylvania, Abramson Cancer Center, Philadelphia, USA; ⁵Medical College of Georgia, Department of Medicine, Augusta, USA; ⁶Chi Mei Hospital, Tainan, Taiwan; ⁷Chang Gung Memorial Hospital, Tao-Yuan, Taiwan; ⁸Exelixis Inc, South San Francisco, USA; ⁹Rocky Mountain Cancer Center, Division of Medical Oncology, Denver, USA

Background: XL184 is an oral, potent inhibitor of MET, VEGFR2 and RET. MET overexpression has been found to correlate with an increased incidence of intrahepatic metastasis and inversely correlated with survival of HCC patients. In addition, HCC is a hypervascular malignancy. Thus co-targeting of the MET and VEGF signaling pathways by XL184 may be a promising treatment strategy. Preliminary data from the open label Lead-in Stage of a Phase 2 randomized discontinuation trial are presented showing the effects of XL184 in pts with HCC.

Methods: HCC pts with a Child-Pugh score of A who failed up to 1 prior treatment regimen are eligible. XL184 is administered open label at 100 mg free base equivalent (125 mg XL184-malate-salt) qd for 12 weeks (wks) (Lead-in Stage). Tumor response per mRECIST is assessed every 6 wks. Pts with partial or complete response (PR or CR) at week (wk) 12 continue to receive XL184; pts with progressive disease (PD) discontinue XL184.

Pts with stable disease (SD) at wk 12 are randomized 1:1 to receive XL184 or placebo. Cross-over from placebo to XL184 is allowed upon PD. Primary endpoints are objective response rate at wk 12 and progression free survival in the Randomized Stage. Pharmacokinetics of XL184 will be analyzed in this hepatically impaired patient population.

Results: A total of 12 pts have been enrolled with a median age of 65 years (M/F 64%/36%). The median number of prior systemic treatments was 1 with 7 pts having received sorafenib. Of the 7 pts who were evaluable (minimum 12 wks follow up) to date, 2 pts achieved a PR and 5 pts achieved SD with radiological evidence of tumor shrinkage. The overall disease control rate at wk 12 was 88%. One pt previously treated with sorafenib showed a 42% tumor decrease at wk 12. Three pts with SD had an AFP reduction of more than 50% at wk 12. The overall dose reduction rate for pts on study for at least 6 wks was 67%. Most frequently observed adverse events regardless of causality with CTCAE Grade ≥ 3 in the Lead-in Stage include diarrhea (n = 2), nausea, fatigue, thrombocytopenia, vomiting, anemia, blister, blood magnesium increased, dehydration, epistaxis, and hypoglycemia (each n = 1).

Conclusions: Preliminary results suggest that XL184 is active in pts with advanced HCC, including those previously treated with sorafenib. Updated efficacy and safety results will be presented.

409

POSTER

The novel, investigational Nedd8-activating enzyme inhibitor MLN4924 in patients with metastatic melanoma: a phase 1 study

O. Hamid¹, B.J. Dezube², M.D. Pickard³, M.A. Shultz⁴, S. Bhatia⁵. ¹The Angeles Clinic and Research Institute, Oncology, Santa Monica CA, USA; ²Millennium Pharmaceuticals Inc., Oncology Clinical Research, Cambridge MA, USA; ³Millennium Pharmaceuticals Inc., Biostatistics, Cambridge MA, USA; ⁴Millennium Pharmaceuticals Inc., Clinical Operations, Cambridge MA, USA; ⁵University of Washington, Department of Medicine, Seattle WA, USA

Background: Metastatic melanoma is associated with poor prognosis; new agents with improved efficacy are needed. The investigational agent MLN4924 is a novel small-molecule inhibitor of Nedd8-activating enzyme (NAE); NAE inhibition prevents the proteasomal degradation of proteins with roles in cell cycle progression (p27), DNA damage (Cdt-1), stress response (Nrf-2), and signal transduction (p130Cas). MLN4924 is active in preclinical models of several tumor types; in patients, pharmacodynamic responses of elevated Cdt-1 and Nrf-2 levels have been seen in post-treatment skin biopsies (Kauh *et al*, ASCO 2009). The primary objectives of this study were to determine the safety profile and maximum tolerated dose (MTD) of MLN4924 in patients with metastatic melanoma.

Materials and Methods: Patients aged ≥ 18 years with ECOG performance status 0–2 were treated with 1-hour intravenous infusions of MLN4924 on days 1, 4, 8, and 11 of 21-day cycles. Dose escalation, starting at 50 mg/m² and using 1.33-fold increments, proceeded via a Bayesian continual reassessment method based on occurrence of dose-limiting toxicities (DLTs) in cycle 1. The primary endpoint included adverse events (AEs). Secondary endpoints included antitumor activity, and the pharmacokinetics (PK) and pharmacodynamics of MLN4924.

Results: To date, 12 patients (8 male; median age 55.5 years, range 34–71; median 2 prior therapies, range 0–5) have been enrolled to 5 dose levels: 50 (n = 2), 67 (n = 2), 89 (n = 2), 118 (n = 4), and 157 mg/m² (n = 2). One DLT, of MLN4924-related grade 3 hypophosphatemia (118 mg/m² dose level), has been recorded to date; the MTD has not been reached. Patients have received a median of 2 cycles (range 0 to 7+). AEs have been mostly mild/moderate (grade 1/2); the most common include nausea (n = 6), fatigue (n = 5; 2 grade 2), myalgia (n = 4), and diarrhea, pruritus, anorexia, and muscle spasms (each n = 3; 1 grade 2 anorexia). Two grade 3 AEs have been reported of cancer-related pain and transient hypophosphatemia. Six patients have discontinued due to progressive disease (1 died). One patient with brain metastases, who had received 4 prior lines of therapy, remains in stable disease after 7 cycles (67 mg/m² dose level). Preliminary evidence for shrinkage/softening of subcutaneous nodules has been seen in 2 patients.

Conclusions: MLN4924 was well tolerated at the current dosing schedule, and encouraging antitumor activity has been observed. Accrual and dose escalation continues. Updated safety and efficacy data, plus PK and pharmacodynamic data, will be presented.

410

POSTER

Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PRECOG, LLC (NCT006872970)

J. Aisner¹, J. Manola², S. Dakhil³, P. Stella⁴, J. Schiller⁵. ¹Cancer Institute of New Jersey, Medicine, New Brunswick, USA; ²Dana Farber Cancer Institute, Biostatistics, Boston, USA; ³Cancer Center of Kansas PA, Medicine, Wichita, USA; ⁴Saint Joseph Mercy Hospital, Medicine, Ann Arbor, USA; ⁵University of Texas Southwestern Medical Center, Medicine, Dallas, USA

Background: The goal was to determine if vandetanib, a dual inhibitor of the VEGF and EGFR pathways, could improve progression-free survival (PFS) in patients (pts) with NSCLC when given as induction therapy (tx) with docetaxel and carboplatin, followed by maintenance tx, compared to maintenance placebo.

Materials and Methods: Pts with advanced stage NSCLC were randomized to receive induction docetaxel (75 mg/m²) + carboplatin (AUC 6) on day 1 of a 21-day cycle and daily vandetanib (100 mg/day po) for 4 cycles, followed by maintenance tx with either daily vandetanib (300 mg/day po) or placebo until progression. The study was designed to demonstrate improvement in PFS with the addition of vandetanib to a median of 6.2 mos, compared to historical control median of 4.5 mos for docetaxel + carboplatin alone. Eligible pts had measurable disease per RECIST, ECOG PS 0 or 1, and no prior cytotoxic or targeted tx for advanced disease. Pts with cardiac conditions including uncontrolled hypertension or history of QT prolongation were ineligible.

Results: 162 pts were randomized between May 2008 and December 2009, of whom 158 received tx. 87% of pts had stage IV/recurrent disease; 52% were male. Median age was 63 (range 36–82). A median of 2 cycles of induction tx were given. Sixty pts received maintenance tx/placebo (median 2 cycles). Tx was discontinued primarily for progression (38%/65% for induction and maintenance) and adverse events (AE) (28%/23%). Common AEs included fatigue, dyspnea, diarrhea, dehydration, neutropenia, neutropenic fever, and leukopenia. Death on tx were reported for 19 pts, 11 from progressive disease. Neither arm demonstrated significant improvement over the historical median PFS of 4.5 mos. Median PFS among pts randomized to maintenance vandetanib was 5.3 mos (95% CI, 3.2–6.5 mos), while median PFS among pts randomized to maintenance placebo was 4.6 mos (95% CI, 2.8–4.9 mos, stratified logrank p = 0.04).

Conclusions: Although neither arm met the primary endpoint over historical control, pts randomized to vandetanib maintenance had longer PFS compared to pts randomized to placebo maintenance.

411

POSTER

A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies

A.P. Moore¹, S. Thomas¹, C.J. Ryan¹, T.M. Jahan¹, S.G. DuBois¹, J.K. Chan², K.T. Thurn¹, A. Reinherth¹, A. Daud¹, P.N. Munster¹. ¹University of California San Francisco, Hematology-Oncology Department, San Francisco CA, USA; ²University of California San Francisco, Gynecologic Oncology, San Francisco CA, USA

Background: Preclinical and clinical data suggest that pre-exposure of cancer cells to a histone deacetylase inhibitor (HDACi) potentiates topoisomerase (topo) inhibitors. The HDACi-induced histone acetylation and chromatin modulation facilitates DNA access and target recruitment for topo II inhibitors. In vitro data further suggest that effective inhibition of HDAC2 is necessary for enhanced epirubicin-induced apoptosis.

Materials/Methods: This phase I trial explores the safety, tolerability, and maximum tolerated dose (MTD) of escalating doses of panobinostat given orally on days 1, 3, and 5 followed by epirubicin administered intravenously at 75 mg/m² on day 5 in 21-day cycles. Histone acetylation and HDAC2 expression are evaluated in pre- and post-treatment peripheral blood mononuclear cells in all patients and in tumor cells of 12 patients treated at the MTD.

Results: The trial enrolled 20 patients [5M/15F, median age 49 years (range 24–80)] in 5 panobinostat cohorts: 20, 30, 40, 50, and 60 mg. The MTD was identified as 50 mg panobinostat. Tumor types included melanoma (n = 6), breast (n = 3), sarcoma (n = 3), ovarian (n = 2), lung (n = 2), and one each of neuroblastoma, pancreatic, testicular, and colon cancer. Dose-limiting toxicities included 1/6 patient with a grade 3 atrial fibrillation in the 50 mg cohort and 2/3 patients in the 60 mg cohort with DLT, one with grade 3 fatigue and one with grade 4 thrombocytopenia. Non-dose-limiting grade 3 and 4 toxicities include neutropenia (n = 12, 60%), thrombocytopenia (n = 4, 20%), and anemia (n = 3, 15%). One patient with small cell lung cancer has an unconfirmed partial response, one patient each (melanoma, ovarian, neuroblastoma) demonstrated stable disease for